UBS analyst Dan Leonard raised the firm’s price target on Repligen (RGEN) to $200 from $190 and keeps a Buy rating on the shares. Repligen’s diverse growth drivers and reshoring opportunities position it well for sustained bioprocessing recovery, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGEN:
- Repligen Appoints Martin Madaus as New Board Chair
- Repligen executive chair Tony Hunt to retire, Martin Madaus to succeed
- Repligen announces launch of three high-performance resins
- Repligen price target raised to $190 from $175 at Wells Fargo
- Repligen price target raised to $200 from $175 at Barclays